Intra-Cellular Therapies, Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Intra-Cellular Therapies, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Intra-Cellular Therapies, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$38.8M, a 30.7% decline year-over-year.
  • Intra-Cellular Therapies, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$122M, a 29.6% increase year-over-year.
  • Intra-Cellular Therapies, Inc. annual Operating Income (Loss) for 2023 was -$159M, a 39.5% increase from 2022.
  • Intra-Cellular Therapies, Inc. annual Operating Income (Loss) for 2022 was -$264M, a 7.72% increase from 2021.
  • Intra-Cellular Therapies, Inc. annual Operating Income (Loss) for 2021 was -$286M, a 23.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$159M +$104M +39.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$264M +$22.1M +7.72% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$286M -$54.5M -23.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$231M -$77.2M -50.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$154M +$8.25M +5.09% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$162M -$59.4M -57.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$103M +$15.4M +13% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$118M -$12.4M -11.8% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$106M -$74.8M -241% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-01
2014 -$31M -$4.72M -18% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 -$26.3M -$9.86M -60.1% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-25
2012 -$16.4M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.